BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 18204078)

  • 1. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice.
    Arlt VM; Stiborová M; Henderson CJ; Thiemann M; Frei E; Aimová D; Singh R; Gamboa da Costa G; Schmitz OJ; Farmer PB; Wolf CR; Phillips DH
    Carcinogenesis; 2008 Mar; 29(3):656-65. PubMed ID: 18204078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse.
    Stiborová M; Arlt VM; Henderson CJ; Wolf CR; Kotrbová V; Moserová M; Hudecek J; Phillips DH; Frei E
    Toxicol Appl Pharmacol; 2008 Feb; 226(3):318-27. PubMed ID: 17976674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome b
    Reed L; Mrizova I; Barta F; Indra R; Moserova M; Kopka K; Schmeiser HH; Wolf CR; Henderson CJ; Stiborova M; Phillips DH; Arlt VM
    Arch Toxicol; 2018 Apr; 92(4):1625-1638. PubMed ID: 29368147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure to benzo[a]pyrene of Hepatic Cytochrome P450 Reductase Null (HRN) and P450 Reductase Conditional Null (RCN) mice: Detection of benzo[a]pyrene diol epoxide-DNA adducts by immunohistochemistry and 32P-postlabelling.
    Arlt VM; Poirier MC; Sykes SE; John K; Moserova M; Stiborova M; Wolf CR; Henderson CJ; Phillips DH
    Toxicol Lett; 2012 Sep; 213(2):160-6. PubMed ID: 22759596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model.
    Levová K; Moserová M; Kotrbová V; Sulc M; Henderson CJ; Wolf CR; Phillips DH; Frei E; Schmeiser HH; Mares J; Arlt VM; Stiborová M
    Toxicol Sci; 2011 May; 121(1):43-56. PubMed ID: 21362632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse.
    Pass GJ; Carrie D; Boylan M; Lorimore S; Wright E; Houston B; Henderson CJ; Wolf CR
    Cancer Res; 2005 May; 65(10):4211-7. PubMed ID: 15899812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deletion of cytochrome P450 oxidoreductase enhances metabolism and DNA adduct formation of benzo[a]pyrene in Hepa1c1c7 cells.
    Reed L; Jarvis IWH; Phillips DH; Arlt VM
    Mutagenesis; 2019 Dec; 34(5-6):413-420. PubMed ID: 31612222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced DNA adduct formation by benzo[a]pyrene in human liver cells lacking cytochrome P450 oxidoreductase.
    Reed L; Jarvis IWH; Phillips DH; Arlt VM
    Mutat Res Genet Toxicol Environ Mutagen; 2020 Apr; 852():503162. PubMed ID: 32265041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome b5 and epoxide hydrolase contribute to benzo[a]pyrene-DNA adduct formation catalyzed by cytochrome P450 1A1 under low NADPH:P450 oxidoreductase conditions.
    Stiborová M; Moserová M; Černá V; Indra R; Dračínský M; Šulc M; Henderson CJ; Wolf CR; Schmeiser HH; Phillips DH; Frei E; Arlt VM
    Toxicology; 2014 Apr; 318():1-12. PubMed ID: 24530354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity.
    Henderson CJ; Pass GJ; Wolf CR
    Toxicol Lett; 2006 Mar; 162(1):111-7. PubMed ID: 16343823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of hepatic cytochrome b
    Reed L; Indra R; Mrizova I; Moserova M; Schmeiser HH; Wolf CR; Henderson CJ; Stiborova M; Phillips DH; Arlt VM
    Toxicol Appl Pharmacol; 2019 Mar; 366():64-74. PubMed ID: 30685480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation and detoxification metabolism of urban air pollutants 2-nitrobenzanthrone and carcinogenic 3-nitrobenzanthrone by rat and mouse hepatic microsomes.
    Stiborova M; Cechova T; Borek-Dohalska L; Moserova M; Frei E; Schmeiser HH; Paca J; Arlt VM
    Neuro Endocrinol Lett; 2012; 33 Suppl 3():8-15. PubMed ID: 23353838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detoxification of benzo[a]pyrene primarily depends on cytochrome P450, while bioactivation involves additional oxidoreductases including 5-lipoxygenase, cyclooxygenase, and aldo-keto reductase in the liver.
    Wang L; Xu W; Ma L; Zhang S; Zhang K; Ye P; Xing G; Zhang X; Cao Y; Xi J; Gu J; Luan Y
    J Biochem Mol Toxicol; 2017 Jul; 31(7):. PubMed ID: 28111842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of hepatic cytochrome P450 (P450) oxidoreductase deficiency on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-DNA adduct formation in P450 reductase conditional null mice.
    Arlt VM; Singh R; Stiborová M; Gamboa da Costa G; Frei E; Evans JD; Farmer PB; Wolf CR; Henderson CJ; Phillips DH
    Drug Metab Dispos; 2011 Dec; 39(12):2169-73. PubMed ID: 21940903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation.
    Uno S; Dalton TP; Derkenne S; Curran CP; Miller ML; Shertzer HG; Nebert DW
    Mol Pharmacol; 2004 May; 65(5):1225-37. PubMed ID: 15102951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro and in vivo benzo[a]pyrene-DNA adduct formation and its relationship to CYP1A activity in two species of ictalurid catfish.
    Ploch SA; King LC; Kohan MJ; Di Giulio RT
    Toxicol Appl Pharmacol; 1998 Mar; 149(1):90-8. PubMed ID: 9512731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro metabolism of benzo[a]pyrene by recombinant zebrafish CYP1A and liver microsomes from beta-naphthoflavone-treated rainbow trout.
    Miranda CL; Chung WG; Wang-Buhler JL; Musafia-Jeknic T; Baird WM; Buhler DR
    Aquat Toxicol; 2006 Nov; 80(2):101-8. PubMed ID: 16963132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of benzo[a]pyrene on metabolic activation of anticancer drug ellipticine in mice.
    Stiborova M; Cerna V; Moserova M; Arlt VM; Frei E
    Neuro Endocrinol Lett; 2013; 34 Suppl 2():43-54. PubMed ID: 24362092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between DNA adduct formation by benzo[a]pyrene and expression of its activation enzyme cytochrome P450 1A1 in rat.
    Hodek P; Koblihová J; Kizek R; Frei E; Arlt VM; Stiborová M
    Environ Toxicol Pharmacol; 2013 Nov; 36(3):989-96. PubMed ID: 24095716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1.
    Shimada T; Hayes CL; Yamazaki H; Amin S; Hecht SS; Guengerich FP; Sutter TR
    Cancer Res; 1996 Jul; 56(13):2979-84. PubMed ID: 8674051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.